12:00 AM
 | 
Jul 14, 2008
 |  BioCentury  |  Emerging Company Profile

Coronado: Cancer conquistador

Coronado Biosciences Inc. has in-licensed cancer candidates that it hopes will improve on the safety profiles of existing drugs. The company initially is targeting small indications to show clinical utility in an effort to attract partners for the pricier development for larger markets.

The company’s lead candidate is CNDO101, a fourth-generation anthracycline in Phase I testing to treat solid tumors. Anthracyclines are one of the most effective classes of chemotherapeutics. Although they are used to treat a wide variety of cancers, they are cardiotoxic and can cause vomiting.

“Anthracyclines can cause irreversible damage to the heart. Physicians limit the dose but would rather not use them,” according to CEO R.J. Tesi.

CNDO101 comes from Gem Pharmaceuticals Inc., a now defunct virtual company that tweaked the anthracycline doxorubicin to limit the compound’s side effects.

“Gem figured out two...

Read the full 679 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >